Cargando…
Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells
Pituitary adenomas, accounting for 15% of diagnosed intracranial neoplasms, are usually benign and pharmacologically and surgically treatable; however, the critical location, mass effects and hormone hypersecretion sustain their significant morbidity. Approximately 35% of pituitary tumors show a les...
Autores principales: | Würth, Roberto, Thellung, Stefano, Corsaro, Alessandro, Barbieri, Federica, Florio, Tullio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044184/ https://www.ncbi.nlm.nih.gov/pubmed/32153500 http://dx.doi.org/10.3389/fendo.2020.00054 |
Ejemplares similares
-
Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System
por: Barbieri, Federica, et al.
Publicado: (2014) -
Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity
por: Thellung, Stefano, et al.
Publicado: (2019) -
Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm
por: Barbieri, Federica, et al.
Publicado: (2013) -
Emerging Role of Cellular Prion Protein in the Maintenance and Expansion of Glioma Stem Cells †
por: Thellung, Stefano, et al.
Publicado: (2019) -
Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells
por: Corsaro, Alessandro, et al.
Publicado: (2016)